Pfiz­er fronts $250M to nab an­ti­sense drug from Akcea/Io­n­is in up to $1.5B deal

Ear­li­er this year, Pfiz­er se­cured ear­ly ap­proval of its tout­ed block­buster — tafamidis — for transthyretin-me­di­at­ed amy­loi­do­sis, a field ini­tial­ly di­vid­ed be­tween Al­ny­lam and Akcea/Io­n­is. Now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.